Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008


Notes payable, less current portion - 119,000

Capital lease obligation, less current portion 22,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies


Preferred stock - $.001 par value; authorized

5,000,000 shares; non-voting; nil shares

outstanding - -

Common stock - $.001 par value; authorized

325,000,000 shares; outstanding - 226,210,617

and 196,112,201, respectively 226,000 196,000

Additional paid-in-capital 246,205,000 224,453,000

Accumulated deficit (230,836,000) (207,660,000)

Total stockholders' equity 15,595,000 16,989,000






2008 2007 2006


Contract manufacturing

revenue $5,897,000 $3,492,000 $3,005,000

License revenue 196,000 216,000 188,000

Total revenues 6,093,000 3,708,000 3,193,000


Cost of contract

manufacturing 4,804,000 3,296,000 3,297,000

Research and development 18,279,000 15,876,000 12,415,000

Selling, general and

administrative 7,150,000 6,446,000 6,564,000

Total costs and

expenses 30,233,000 25,618,000 22,276,000

LOSS FROM OPERATIONS (24,140,000) (21,910,000) (19,08

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
(Date:8/21/2014)... (PRWEB) August 21, 2014 On Wednesday of ... gel to use Redox Signaling molecules, became available for purchase ... overwhelming. , "The way that RENU 28 works is, if ... slowing down of the rate of cellular renewal within your ... the increasing of that rate of cellular renewal. What RENU ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/19/2014)... NJ (PRWEB) August 20, 2014 ... and regenerative medicine is an inadequate vascular supply. ... constructs and decellularized tissues is critical for successful ... have attempted to mitigate deficiencies in vascularization and ... adding scaffold bioactivity, optimizing scaffold design and architecture, ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Compound, 1-TDC, SAN DIEGO, Oct. 9 ... appointment of Dr. Thomas Van,Dyke to its Medical ... to,Imagenetix on their experimental compound, 1-TDC, for the ... is Professor, Department of,Periodontology and Oral Biology, Boston ...
... Oct. 9 BioElectronics,Corporation, (Pink Sheets: BIEL), ... has cleared ActiPatch for sale by its,distributor, ... that the experienced sales professionals of,Endotherapeutics will ... team has many decades of experience in ...
... Nanoscale devices present a unique challenge to any optical ... to travel in a straight line. , On the ... light between two surfaces very close together (sometimes as ... the light. Light behaves much differently on the nanoscale ...
Cached Biology Technology:Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board 2Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board 3Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Taming tiny, unruly waves for nano optics 2
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
(Date:8/20/2014)... image of the Para and Mato Grosso states of ... set in order to deforest the land. Deforestation is ... where the land is thereafter converted to a nonforest ... farms, ranches, or urban use. The herringbone-patterned tan lines ... in the middle of the image are evidence of ...
(Date:8/20/2014)... Cancer Research UK scientists have discovered that acral melanomas ... Bob Marley,s death are genetically distinct from other more ... is external) published in the journal Pigment Cell & ... palms of the hands, soles of the feet, nail-beds and ... types of melanoma, it,s not caused by UV damage from ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Scientists learn more about rare skin cancer that killed Bob Marley 2
... -- A few came. They ran. They left. As a ... training in 2008 in new running suits chosen after tests ... The experience was enough to make both the University ... unaware that it was InSport,s training clothes that they had ...
... A new book by researchers at the Hebrew ... mouse demonstrates a surprising similarity between mice and humans. ... a team from the Hebrew University Bone Laboratory consisting of ... and Dr. Yankel Gabet. Also participating in the writing of ...
... YORK (October 9, 2007) -- When its time for ... they head to where it is safest from predators ... study by the Wildlife Conservation Society. Published in ... that moose avoid predation of their calves by grizzly ...
Cached Biology News:Marines land at UO, leave with plans to wear Oregon-made training suits 2Marines land at UO, leave with plans to wear Oregon-made training suits 3Of mice and men: similarities between skeletons of both 2
SAPK/JNK Antibody...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Component in MasterPure™ Purification Kits...
Biology Products: